Pediapharm Files Corporate Presentation
13 September 2018 - 5:17AM
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE
SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO
COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED
STATES SECURITIES LAW.
Pediapharm Inc. ("
Pediapharm") (TSXV:PDP)
(OTCQX:PDDPF) announces that, further to its press release issued
on September 6, 2018, it has filed a corporate presentation on its
website setting out further information about the proposed
acquisition of Medac Pharma, Inc. and the proposed acquisition of
Medexus Inc. The corporate presentation can be viewed at
http://www.pedia-pharm.com.
About Pediapharm
Pediapharm is the only Canadian specialty
pharmaceutical company dedicated to serving the needs of the
pediatric community. Its mission is to bring to the Canadian
market the latest innovative pediatric products with the objective
to improve the health and the well-being of children in Canada.
Since its debut in 2008, Pediapharm has entered into numerous
commercial agreements with partners from Canada and other countries
around the world. Pediapharm’s innovative product portfolio
includes NYDA®, a breakthrough treatment for head lice; Relaxa™, an
osmotic laxative used to treat constipation; EpiCeram®, a
non-steroid emulsion for eczema; naproxen suspension, indicated to
treat pain and inflammation due to various conditions, including
Juvenile Idiopathic Arthritis; Rupall™, an innovative new allergy
medication with a unique mode of action; Otixal™, the first and
only antibiotic and steroid combination ear drop available in
single, sterile, preservative-free and unit-dose packaging; and
Cuvposa™, for chronic severe drooling, a condition affecting a
significant proportion of cerebral palsy patients.
For more information, please
contact:
Sylvain Chretien, President and Chief Executive
OfficerPediapharm Inc.Tel.: 514-762-2626 ext. 201E-mail:
sylvain.chretien@pedia-pharm.com
Roland Boivin, Chief Financial OfficerPediapharm
Inc.Tel.: 514-762-2626 ext. 202E-mail:
roland.boivin@pedia-pharm.com
Frank CandidoDirect Financial Strategies and
Communication Inc.Tel. 514-969-5530E-mail: directmtl@gmail.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
This press release is not an offer of the
securities for sale in the United States. The securities may not be
offered or sold in the United States absent registration or an
exemption from registration. The securities will not be publicly
offered in the United States. The securities have not been and will
not be registered under the U.S. Securities Act, or any state
securities laws.
READER ADVISORIES
Forward Looking Statements
This press release contains “forward-looking
information” within the meaning of applicable securities
legislation. Forward-looking information includes, but is not
limited to, statements with respect to Pediapharm’s future business
operations and the opinions or beliefs of management and future
business goals. All statements, other than of historical fact, that
address activities, events or developments that Pediapharm
believes, expects or anticipates will or may occur in the future
(including, without limitation, statements regarding potential
acquisitions and financings) are forward-looking statements.
Forward-looking statements are generally identifiable by use of the
words “may”, “will”, “should”, “continue”, “expect”, “anticipate”,
“estimate”, “believe”, “intend”, “plan” or “project” or the
negative of these words or other variations on these words or
comparable terminology. Forward-looking statements are subject to a
number of risks and uncertainties, many of which are beyond
Pediapharm's ability to control or predict, that may cause the
actual results of Pediapharm to differ materially from those
discussed in the forward-looking statements. Factors that could
cause actual results or events to differ materially from current
expectations include, among other things, without limitation, risks
disclosed in Pediapharm's public disclosure record on file with the
relevant securities regulatory authorities. Although Pediapharm
believes that the expectations and assumptions on which such
forward-looking information is based are reasonable, undue reliance
should not be placed on the forward-looking information because
Pediapharm can give no assurance that they will prove to be
correct. Since forward-looking information addresses future events
and conditions, by its very nature they involve inherent risks and
uncertainties. Pediapharm’s actual results, performance or
achievement could differ materially from those expressed in, or
implied by, the forward-looking information and, accordingly, no
assurance can be given that any of the events anticipated by the
forward-looking information will transpire or occur, or if any of
them do so, what benefits that Pediapharm will derive therefrom.
Management has included the above summary of assumptions and risks
related to forward-looking information provided in this press
release in order to provide securityholders with a more complete
perspective on Pediapharm's future operations and such information
may not be appropriate for other purposes. Readers should not place
undue reliance on forward-looking statements. Readers are cautioned
that the foregoing lists of factors are not exhaustive. Additional
information on these and other factors that could affect
Pediapharm's operations or financial results are included in
reports on file with applicable securities regulatory authorities
and may be accessed through the SEDAR website (www.sedar.com). The
forward-looking statements included in this news release are made
as of the date of this news release and Pediapharm does not
undertake an obligation to publicly update such forward-looking
statements to reflect new information, subsequent events or
otherwise unless required by applicable securities
legislation.
Pediapharm Inc. (TSXV:PDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pediapharm Inc. (TSXV:PDP)
Historical Stock Chart
From Jul 2023 to Jul 2024